Skip to main content
OpenTrials
Completed

NCT Number: NCT01179958

Cognitive Benefits of Aerobic Exercise Across the Age Span

The purpose of this study is to test the hypothesis that aerobic exercise leads improved cognitive function accompanied by increases in gray matter density and changes in functional magnetic resonance imaging (fMRI) patterns of task-related activation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–68 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Richard Sloan

New York, 10013, United States

About this study

While animal and human studies indicate cognitive benefits from aerobic exercise across the lifespan, the great majority of controlled exercise studies in humans have been restricted to elderly individuals. Those studies have indicated that enhancing aerobic capacity has a beneficial effect on cognition. One study suggests that this benefit is seen particularly for executive control processes, precisely the processes affected by aging. These improvements have been accompanied by increases in gray matter density and changes in functional magnetic resonance imaging (fMRI) patterns of task-related activation. The goal of the proposed study is to extend the investigation of the beneficial effects of aerobic exercise to younger individuals, and to compare these effects in young and old.

In this application the study team propose to conduct a study in which 270 sedentary but otherwise healthy and cognitively intact individuals in the 20-68 year age range are randomized to two training conditions, aerobic exercise and stretching/toning, to be completed at YMCAs and YMHAs in New York City. Participants will be assessed for aerobic capacity, cognitive task performance, and by structural MRI, resting cerebral blood flow scans (arterial spin labeling) and cognitive activation fMRI studies at study entry and after 6 months of training.

The study also proposes two complementary approaches to investigating the neural correlates of the beneficial effects of aerobic exercise on cognition: 1) imaging -- a combination of structural, metabolic, and cognitive activation fMRI studies to evaluate the neural substrates of the effect of aerobic exercise on cognition will be used. 2) important correlates -- the effects of apolipoprotein E (APOE) genotype, inflammatory markers and cognitive reserve on the cognitive effects of aerobic exercise will be explored.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 20-68
  • English-speaking
  • strongly right-handed
  • BMI < 35
  • Pre-menopausal (women only): no oral contraceptive use Post-menopausal: no estrogen replacement therapy
  • sedentary: VO2 max < 41 and 31.6 ml/kg/min for men age 20-40 and 50-68 and < 35.2 and 26.6 ml/kg/min for women age 20-40 and 50-68 respectively
  • participants over age 60 must have ECG within past 3 months

Exclusion criteria

  • MRI contraindications (e.g., metallic implants, pacemaker, weight > 350 lbs, waist > 55")
  • Hearing impaired/hearing aids, unable to read newspaper at arm's length with corrective lenses
  • Objective cognitive impairment
  • Ischemic changes, abnormal blood pressure responses, or any significant ectopy during aerobic capacity testing
  • Cardiovascular disease
  • Uncontrolled high blood pressure (systolic blood pressure ≥ 140 mmHg; or diastolic blood pressure ≥ 90 mmHg on two measures)
  • Current or recent (evidence of disease x 5 years) non-skin neoplastic disease or melanoma
  • Active hepatic disease (not a history of hepatitis) or primary renal disease requiring dialysis, primary untreated endocrine diseases, e.g., Cushing's disease or primary hypothalamic failure or insulin dependent diabetes (Type I or II).
  • HIV infection
  • Pregnant or lactating (participation allowed 3 months after ceasing lactation
  • Medications that target CNS (central nervous system, e.g., neuroleptics, anticonvulsants, antidepressants, benzodiazepines) within the last month
  • Women: any selective estrogen receptor modulator or aromatase inhibitor Men: androgen ablation/deprivation hormonal therapies
  • Any history of psychosis or electroconvulsive therapy
  • Psychotic disorder (lifetime)
  • Current or recent (within past 12 months) alcohol or substance abuse or dependence. Recent use (past month) of recreational drugs.
  • Brain disorder such as stroke, tumor, infection, epilepsy, multiple sclerosis, degenerative diseases, head injury, mental retardation
  • Imaged cortical stroke or large subcortical lacunae or infarct or space-occupying lesion (≥ 2 cubic cm). Other findings, e.g., periventricular caps or small white matter hyperintensities, do not result in exclusion
  • Diagnosed learning disability, dyslexia
  • Current or recent (Past 5 years) Major Depressive Disorder, Bipolar Disorder, or Anxiety Disorder
  • Dementia Rating Scale < 135

Treatment and study plan

Aerobic training

Behavioral

24 weeks of aerobic training, 4X/week

Other names: Training, aerobic

stretching/toning

Behavioral

stretches and toning exercises designed to promote flexibility and improved core strength

Other names: Exercises, stretches and toning

Primary outcomes

  1. Change from baseline in measures of executive control function and episodic memory at 6 months

    Time frame: 24 weeks

    tests of global intelligence, executive function, working memory and processing speed

Secondary outcomes

  1. Change from baseline in brain structure, resting cerebral blood flow and network efficiency at 6 months

    Time frame: 24 weeks

    structural MRI (for gray matter density), resting CBF (cerebral blood flow, measured by arterial spin labeling) and cognitive activation fMRI studies

  2. Change from baseline in measures of interleukin-6, tumor necrosis factor alpha, C-reactive protein at 6 months

    Time frame: Baseline and 24 weeks

  3. Change from baseline in aerobic capacity at 6 months

    Time frame: 24 weeks

    aerobic capacity as measured by VO2 max

  4. Change from baseline in measures of executive control function and episodic memory at 1 year

    Time frame: 48 weeks

    tests of global intelligence, executive function, working memory and processing speed

Sponsors and collaborators

Lead sponsor

New York State Psychiatric Institute

Other

Registry information

Important dates

Study start
2010
Primary completion
2016
Study completion
2016
First posted
Aug 11, 2010
Registry last updated
Aug 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.